Captopril in the hepatorenal syndrome

Area of Science:

• Nephrology
• Gastroenterology
• Pharmacology

Background:

• Hepatorenal syndrome (HRS) is a severe complication of advanced liver disease.
• The renin-angiotensin system is often implicated in the pathophysiology of HRS.
• Effective treatments for HRS remain limited.

Purpose of the Study:

• To evaluate the efficacy of captopril, an angiotensin-converting enzyme inhibitor, in patients with hepatorenal syndrome.
• To assess the impact of captopril on renal function and urinary sodium excretion in HRS.
• To investigate the role of the renin-angiotensin system in HRS progression.

Main Methods:

• Five patients diagnosed with hepatorenal syndrome were enrolled.
• Patients received oral captopril at dosages of 25 or 50 mg every 6 hours for up to 48 hours.
• Renal function, urinary sodium concentration, and overall outcome were monitored.

Main Results:

• Only one patient experienced a significant increase in urinary sodium concentration, without diuresis.
• All patients exhibited continued deterioration of renal function, characterized by persistent oliguria and rising serum creatinine.
• The study observed a uniformly fatal outcome among the treated patients.

Conclusions:

• Standard dosages of captopril demonstrated no therapeutic benefit in patients with hepatorenal syndrome.
• The findings suggest that alterations in the renin-angiotensin system in HRS may be secondary to reduced renal perfusion.
• Further research is needed to explore alternative therapeutic strategies for hepatorenal syndrome.